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Smumary Recent studies have shown that the use of cytokines such as granulocyte colony-stimulating factor
(G-CSF) to ameliorate chemotherapy-induced myelosuppression may enhance the viability of tumour cells
with functional receptors for these cytokines. In this study, therefore, we used murine bone marrow (BM) cells
in an in vitro model in an attempt to determine whether topoisomerase inhibitors (camptothecin, etoposide and
doxorubicin) induce myelosuppression (BM cell death) and whether novel treatments other than the admini-
stration of G-CSF can be used for rescue from myelosuppression. DNA fragmentation assay, ultrasuctural
analysis and cell cycle analysis demonstrated that these chemotherapeutic agents induced apoptosis in BM
cells. We demonstrated in addition that enforced expression of the bcl-2 gene in BM cells by MPZenNeo
(bcl-2) retroviral gene transfer increased resistance to the apoptosis induced by these agents. Thes findings
suggest the possibility that enforced expression of the bdl-2 gene in BM cells using gene transfer techniques
may enable rescue from chemotherapy-induced myelosuppression.
The intensive use of chemotherapeutic agents is a mainstay in
the current treatment of malignant diseases. However,
myelosuppression is a common and serious complication of
treatment with these agents since most lack specificity for
malignant cells. Therefore, reduction in the degree of dura-
tion of chemotherapy-induced myelosuppression may
decrease the morbidity ofchemotherapy and enhance tumour
control.
In general, rhG-CSF is well tolerated within a range of
doses effective in increasing the rate ofmyeloid recovery after
high-dose chemotherapy (Antman et al., 1988; Brandt et al.,
1988). However, Lotem and Sachs (1992) have recently sug-
gested that the use of cytokines such as G-CSF to ameliorate
myelosuppression that follows the use of chemotherapeutic
agents or radiation in cancer therapy may not only stimulate
the recovery of normal hematopoietic cells but also enhance
the viability of leukaemic cells or non-haematopoietic tumour
cells with functional receptors for these cytokines. Therefore,
in the case of tumours with G-CSF receptors, the application
of novel treatments other than the administration of rhGM-
CSF will be necessary for amelioration of the myelosuppres-
sion induced by chemotherapy.
While much information is available on the cellular targets
and mechanisms of action of chemotherapeutic agents, little
is known about how they actually induce cell death. Recent
studies have shown that the most likely mechanism of cell
death following exposure to chemotherapeutic agents is
apoptosis (programmed cell death) (Eastman, 1990; Martin
et al., 1990; Sorenson et al., 1990; Martin & Cotter, 1991;
Walker et al., 1991; Onishi et al., 1993). Therefore, apoptosis
of bone marrow (BM) cells may be the main mechanism of
myelosuppression.
Drugs that interact with DNA topoisomerase, such as
CPT, VP-16 and doxorubicin, have been found to be partic-
ularly useful in chemotherapeutic treatment, but do tend to
induce myelosuppression (Glisson & Ross, 1987; Kohn et al.,
1987; Zwelling, 1989). Recently, CPT and VP-16 have been
shown to induce apoptosis with DNA cleavage in thymocytes
(Walker et al., 1991; Onishi et al., 1993) and in concanavalin
A-stimulated splenocytes (Jaxel et al., 1988). In addition,
doxorubicin is known to induce apoptosis in the murine
small intestinal tract (Thakkar & Potten, 1992) and in
thymocytes (Onishi et al., 1993). In this study, therefore, we
used DNA fragmentation assay, ultrastructual analysis and
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cell cycle analysis in attempting to determine whether CPT,
VP-16 and doxorubicin induce apoptosis in murine BM cells.
On the other hand, forced expression of bcl-2, a gene
implicated in the genesis of follicular lymphoma (Tsujimoto
et al., 1984; Bakhshi et al., 1985; Cleary & Sklar, 1986), has
been shown to prevent apoptosis offactor-dependent myeloid
cells and pro-B-cell lines cultured in the absence of growth
factor (Cleary & Sklar, 1985; Vaux et al., 1988). In addition,
expression of bcl-2 has been shown to increase the resistance
of cells to ethanol, methotrexate and heat shock (Nunez et
al., 1990). We therefore wished to determine whether the
bcl-2 gene could prevent BM cell death induced by
chemotherapeutic agents. Accordingly, we introduced a
human bcl-2 gene into BM cells by MPZenNeo (bcl-2) ret-
roviral gene transfer (Cleary & Sklar, 1985; Tsujimoto, 1989).
In this study, we also attempted to determine whether a
high rate of expression of the bcl-2 gene in BM cells can
prevent cell death induced by chemotherapy.
Materiak and methods
Bone marrow cells
Murine bone marrow (BM) cells were obtained from the
femurs of 5- to 6-week-old Balb/c female mice. Marrow plugs
were flushed out with phosphate-buffered saline (PBS), pas-
saged through a 23 gauge needle, washed and resuspended in
complete RPMI-1640 medium supplemented with 10% heat-
inactivated fetal calf serum (FCS) (Gibco, Grand Island, NY,
USA), 4mM glutamine, 50 U mld I penicilln and 50;Lg ml 1I
streptomycin at a density of 106 cells ml1'. Macrophages and
other adherent cells were removed after an 18 h period of
incubation at 37C in 5% carbon dioxide in tissue culture
flasks as previously described (Strassman et al., 1988). Non-
adherent cells were collected and resuspended in complete
medium and cultured with 1Ongml1 rhG-CSF kindly supp-
lied by Chugai Pharmaceuticals (Tokyo, Japan).
Chemotherapeutic agents
CPT was purchased from Sigma (St Louis, MO, USA).
VP-16 was a generous gift from Nippon Kayaku (Tokyo,
Japan). These agents were obtained in powder form, from
which 3.5mgml-' or l0mgml-' stock solution was
prepared in dimethylsulphoxide. Doxorubicin was a generous
gift from Kyowa Hakko Kogyo (Tokyo). It was also
obtained in powder form, from which a 1.0mgml' stock
solution was prepared in normal saline.
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Retroviru infection
A 942 bp blunted (EcoRIITaqI cDNA fragment containing
the entire human bcl-2 coding sequence (Tsujimoto, 1989)
was inserted into the blunted XhoI site of the retroviral
vector MPZenSVNeo, allowing expression of bcl-2 from the
MPSV long terminal repeat (Cleary & Sklar, 1985; Hariharan
et al., 1988). Murine fibroblast lnes secreting MPZenNeo
(bcl-2) or MPZenNeo virus free ofhelper virus were obtained
by electroporating the *2 packaging line (Mann et al., 1983)
with retroviral plasmid DNA. BM cells were infected by
adding the filtered superatant of the virus-producing *2
fibroblast cells with incubation for 24h. Infected BM cells
were seected in 800pgml'l G418. The production of the
bcl-2 gene in BM cells was asd by immunoprecipitation
using anti-human Bcl-2 MAb (Biochemicals, Tokyo, Japan).
Immwnoprecipitation
BM cells were washed with methionine-free medium contain-
ing 5% FCS, suspended at 2.5 x 10' cells ml-1 in the same
medium supplemented with 250 LCi ml' [35SpL-methionine
(Amersham, Arlington Heights, IL, USA) and cultivated for
5 h. The cells were harvested, washed with PBS and lysed as
previously described (Kondo et al., 1992). The lysate was
mixed with anti-human Bcl-2 MAb, and the immune com-
plexes were precipitated with protein A-Sepharose (Amer-
sham) and analysed on a 12% sodium dodecyl sul-
phate-polyacrylamide gel.
Cell viability asays
BM cells were seeded at 10' cells per well (1.0ml) in 24-well
plates and treated with various chemotherapeutic agents at
clinically reklvant concentrations. Each day an aliquot was
examined microscopially using trypan blue to determine
percentage cell viability.
Inhibition ofRNA andprotein synthesis
To determine whether inhibition of RNA or protein synthesis
results in inhibition of the cytotoxcity induced by
chemotherapeutic agents, BM cells were pretreated for
15 min with actinomycin D (80 ngml-') or cycloheximide
(0.7jAgml-') prior to chemotherapy. Higher concentrations
of actinomycin D and cycloheximide caused cytotoxcity in
BM cells by themselves. Changes in cytotoxcity were deter-
mined by trypan blue exclusion.
Analysis ofDNAfragmentation in agarose gel
This assay was performed as previously decibed (Ishida et
al., 1992). Brifly, harvested BM cells (I x 10') were centri-
fuged and washed twice with cold PBS. The cell pdet was
lysed in l.Oml of a buffer consisting of IOmm Tris-HCL
10mM EDTA and 0.2% Triton X-100 (pH 7.5). After 10min
on ice, the lysate was centrifiged (13,000g) for 10 min at 4C
in an Eppendorf microfuge. Tben, the supernatant (contain-
ing RNA and fragmented DNA, but not intact chromatin)
was extacted first with phenol and then with phenol-chioro-
form:isoamyl alcohol (24:1). The aqueous phase was made
to 300mM sodium chloride and nuceic acids were pre-
cipitated with two vohlm of ethanol. The pelet was rinsed
with 70% ethanol, air dried and dissolved in 20p1 of 1Omm
Tris-HC-1 mM EDTA (pH 7.5). Following digestion of
RNA with RNAse A (0.6mgml-', at 37C for 30min), the
sample was electrophoresed in a 2% agarose gel with Boyer's
buffer (50mM Tris-HCl, 20mM sodium acetate, 2 mM
EDTA and 18 mM sodium chloride, pH 8.05). DNA was
then visualised with ethidium bromide staining.
Ultrastructural analysis
To determine morphologically whether apoptosis is induced
in BM cells by topoisomerase inhibitors, parental and bcl-2-
expressing BM cells treated with lOagml ' VP-16 for 48h
were examined at the ultrastructural level. Briefly, 2 x 10'
BM cells were harvested, washed in PBS, pelleted, prefixed in
2.0% glutaraldehyde for 2 h and washed in 0.1 M phosphate
buffer (pH 7.4), followed by post-fixation with 1.0% osmium
tetroxide for 2 h. Samples were embedded in Econ 812, sec-
tioned and stained for 20 mm in 2.0% aqueous uranyl
acetate and for 2 min in lead citrate. Grids were viewed using
a JEM-1200EX electron microscope (NEC, Toklyo, Japan).
Flow cytometry
Parental and bcl-2-expressing BM cells were treated with
l0Ijgml-I VP-16 for 48h. Then, 2.0x 10' cells were fixed
with 2ml of 70% ethanol on ice for 15min, pelleted and
stained with propidium iodide (50jagml-' in PBS) containing
0.5 mgml-' RNAse A for an additional 30 min on ice, prior
to analysis of DNA content by flow cytometry. Cells were
tested for cell cycle position using a FACScan flow cytometer
(Becton Dickinson, Mountain View, CA, USA) equipped
with CedlFIT version 2.0 software. The SOBR (sum of
broadened rectangles) model provided by this software was
used to estimate the percentage of cells in each phase of the
cell cycles. This model uses a complex repetitive calculation
to produced approximations to the actual histogram, fitting
GO/GI and G2/M populations with single Gaussian curves.
Resaks
BM cell viability
When assayed 7 days after adding 3.5jgml-' CPIT,
lOagml-' VP-16 or lOjgml'- doxorubicin to cultures,
parental BM cells were nearly all dead (Figure 1). In con-
trast, the survival of BM cells cultured in the presence of
actinomycin D or cycloheximide was maintained at > 50%
for at least 7 days. These results indicate the loss of BM cell
viability induced by CPI, VP-16 or doxorubicin is almost
dependent on RNA and protein synthesis. To determine
whether Bc-2 prevents loss of viability induced by these
agents, we infected BM cls with a retrovis bearing genes
for both Bcl-2 and G418 resistance or a control virus bearing
the gene for G418 resistance alone. Expression of the intro-
duced bdl-2 gene was confirmed by immunoprecipitation
using anti-human Bcl-2 MAb (Figure 2), and the expression
of Bcl-2 protein was maintained for at kast 1 month (data
not shown). On the other hand, endogenous expression of
Bcl-2 in parental BM cells was not d d by this MAb
(Figure 2). This MAb does not pick up mouse Bcl-2 protein
according to the manufacturer's protocoL but mature
polymorphonuclear BM cells are shown to be essentally
negative for Bc-2 epression (Hockenbery et al., 1991).
Tbherore, we suggest that endogeous ecpression of Bcl-2 in
BM cells may be very less than exogenous expresson and not
infuee our rult. In addition, subdoning was un ry
to achieve BM cells with high lvls of bcl-2 expression
because the gene transfer ecncy was high (positive
cells>90%, determined by an indirect mmunofluoresnce
meod using anti-human Bcl-2 MAb), and transfected BM
cells showed the alnost same kvel of bcl-2 expression (data
not shown). About 75% ofb-2-expressing BM cells exposed
to chemotherapeutic agents i viable after 7 days
(Figure 1). In contrast, BM cells expressig No alone lost
viability to the same extent as did the uninfected, parental
BM cells. These findings demonstrate that enforced expres-
sion of bcl-2 increased the istance of BM cells to
chemotherapeutic agents
DNAfragmentation
DNA fragmentation in BM cells exposed to 3.5jgml-'
CPT, 10jgml-' VP-16 or 10jgml-' doxorubicin for 48 h at
3TC was determined. Figure 3 shows that the DNA of
bcl-2-expressng BM cells was intact, whereas that of
uninfected BM cells and those expressing Neo alone wasbcl-2 RESCUES MYELOSLPPRESSION 423
broken into nucleosome-sized fragments. These results dem-
onstrate that the expression of bcl-2 gene was nearly
sufficient to maintain the integrity of DNA in BM cells
treated with chemotherapeutic agents.
Ultrastructural appearance
Figure 4 shows that parental BM cells treated with VP-16
lost viability and frequently displayed typical apoptotic mor-
phology including chromatin condensation, while the
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viability of bcl-2-expressing BM cells remained high. How-
ever, about 20% ofbcl-2-expressing BM cells were also dead;
the mechanism of cell death was apoptosis (data not shown).
Cell cycle
We examined the changes in the intensity of fluorescence of
DNA using flow cytometry. As shown in Figure 5, VP-16
treatment of parental BM cells resulted in a decrease in the
percentage of cells in GO/GI phase and an increase in percen-
tage of cells in S and G2/M phases, compared with the
corresponding percentage for the control. Moreover, treat-
ment of parental BM cells with VP-16 resulted in the
accumulation of a discrete subpopulation of signals under the
GO/G, cell cycle region (AO peak). In contrast, bcl-2 inhibited
the appearance of this sub-GO/G, peak in the DNA histo-
grams.
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Fure 2 Immunoprecipitation with anti-human Bcl-2 MAb.
Parental (lane 1), bcl-2-infected (lane 2) and neo-infected (lane 3)
BM cells were labelled with [35SJL-methionine, lysed and
immunoprecipitated with anti-human Bcl-2 MAb. The
immunoprecipitates were analysed on a 12% sodium dodecyl
sulphate-polyacrylamide gel.
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Fuge 1 Survival kinetics of BM cells exposed to CPT
(3.5jAgml ', a), VP-16 (lOggml ', b) or doxorubicin
(10 lg ml-', c). BM cells were seeded at a density of IW0 cells
ml-' and incubated at 37C. Viability was determined at each
time point by trypan blue exchlsion. Values represent the
mean ± s.d. of results of three experiments. 0, * or +, parental
BM cells in the absence or in the presence of actinomycin D
(80ngml-') or cycloheximide (O.7 .gmlV'); A, neo-expressing
BM cells; 0, bcl-2-expressing BM cells.
Fge 3 Induction of DNA fragmentation by chemotherapeutic
agents. DNA fragmentation was assessed for parental (lane 2, 5,
or 8), neo-(lane 3, 6 or 9) and bcl-2-expressing (lane 4, 7 or 10)
BM cells treated with CPT (3.5 LgmJi'; lanes 2-4), VP-16
(10jug mlP'; lanes 5-7) or doxorubicin (10iLg ml' -; lanes 8-10)
for 48 h. Fragmented DNA was electrophoresed in a 2.0%
agarose gel containing 0.5,gml-' ethidium bromide. Molecular
weight standards of multiples of 123-bp DNA ladder (Gibco
BRL, Tokyo) are shown in lane 1.424 S. KONDO et al.
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Fwe 4 Ultrastructural appearance of parental a, and bcl-2-
expressing b, BM cells treated with I0 igml' V-P-16 for 48h
( x 5,600). Arrow indicates condensed chromatin.
Nuclear enzymes, in particular DNA topoisomerases, func-
tion in cellular proliferation and differentiation by inducing
changes in the topology of DNA, enabling DNA synthesis,
recombination and transcription (Wang, 1985; Liu, 1989).
During topological transformation reactions, topoisomerase I
generates transient single-strand DNA breaks and relieves
torsional stress by untwisting the DNA helix, while
topoisomerase II introduces transient double-strand DNA
breaks, resolves DNA molecule tangles, and untwists the
DNA helix. CPT has been shown to inhibit topoisomerase I
through the formation of stable topoisomerase I-DNA
cleavable complexes. Also, anti-tumour agents such as
epipodophyllotoxin (VP-16) and doxorubicin (Adriamycin)
have been thought to exert effects via interaction with
topoisomerase II. However, the exact mechanism by which
interaction of these agents with the topoisomerase I or
11-DNA cleavable complex leads to cell death is unclear. In
this study, we show that topoisomerase inhibitors induce
apoptosis in BM cells in the presence of new RNA and
protein synthesis. This active process, apoptosis of BM cells,
may be the main mechanism of drug-induced myelosuppres-
sion, since the nadir of peripheral neutrophils occurred
usually on days 7-10 post treatment of VP-16 and dox-
orubicin (Wakui et al., 1986; Bronchud et al., 1989).
In this study, in addition, VP-16 induced a marked reduc-
tion in GO/GI phase cells and a large increase in the number
of S and G2/M cells. These findings suggest two possibilities:
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Fie 5 Flow cytometric analysis of BM cells treated without
(controL a) or with 10fig ml'l VP-16, b or c, for 48 h. Parental a
or b and bcd-2-expressing c, BM cells were subsequently fixed and
stained with propidium iodide prior to DNA histogram analysis.
In each case cell number (ordinate) was plotted against relative
fluorescence intensity (abscissa). The percentages of cells in each
phase of the cell cycle at AO (a subpopulation of signals under the
GO/GI cell cycle region): GxjG1:S:G_/M: a, 0:48:47:5; b,
11:14:53:22; c, 0:59:30:1 1.
that BM cell death occurs directly out of GO/GI phase or,
alternatively, that cells continue to cycle in the presence of
VP-16 and die at a later stage in the cell cycle. Moreover, the
accumulation of AO peak was shown; this peak has been
shown to indicate the presence of apoptotic cells (Telford et
al., 1991; Walker et al., 1991; Del Bino et al., 1992). In
general, topoisomerase II inhibitors are thought to kill pro-
liferating cells by inhibiting topoisomerase II and preventing
the cells from either completing S phase or undergoing
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chromosome segregation at mitosis since these are two cel-
lular processes that have an absolute requirement for the
enzyme (Walker et al.. 1991). This cytotoxicity has been
shown to correlate with drug-induced DNA cleavage and to
increase when the drugs are administered during these phases
of the cell cycle (Long & Stringfellow, 1988). In contrast.
Estey et al. (1987) indicate that cells are hypersensitive to
topoisomerase II inhibitors in mitosis but that the hypersen-
sitivity does not correlate with cytotoxicity. Furthermore.
Kaufmann (1988) has demonstrated that there is no direct
correlation between the ability of topoisomerase II inhibitors
to cause DNA strand breaks and their ability to induce cell
death via apoptosis. Topoisomerase II inhibitor-induced
strand breaks are rapidly resealed after removal of the drugs,
while this resealing does not inhibit the onset of apoptosis.
Taken together, further experiments are necessary to deter-
mine during which phase apoptosis in BM cells is occurrng.
The proto-oncogene bcl-2 was discovered as a result of its
translocation to the immunoglobulin heavy-chain locus in
most cases of human follicular centre B-cell lymphoma
(Bakhshi et al., 1985; Cleary & Sklar, 1985; Vaux et al..
1988). This t(14;18) chromosomal translocation spares the
coding region of the bcl-2 gene but appears to deregulate its
expression. The bct-2 gene encodes a cytoplasmic protein
(Tsujimoto et al., 1987; Chen-Levy et al., 1989) that appears
to be associated with the inner membrane of the mitochond-
ria (Hockenbery et al., 1990). Insight into the biological
function of Bcl-2 came with the discovery that enforced bc1-2
expression delays the death of certain haematopoietic cell
lines deprived of growth factor (Cleary & Sklar, 1985). How-
ever, the mechanism by which the bcl-2 gene regulates cell
viability remains unclear, since the predicted amino acid
sequence of the protein it codes for bears no significant
homology to other known proteins and no biochemical
activity has yet been ascribed to it (Miyashita & Reed, 1992).
More recently, Hockenbery et al. (1993) demonstrate that
Bcl-2 functions in an antioxidant pathway to prevent apop-
tosis. Moreover, transgenic mice expressing a bcl-2 gene sub-
jected to an immunoglobulin enhancer contain a large excess
of B lymphocytes with enhanced survival capacity that may
progress into high-grade lymphoma or autoimmune disease
(McDonnell et al., 1990; Strasser et al.. 1991), and Bcl-2
confers survival advantage on Epstein-Barr virus-infected B
cells (Nunez et al., 1990; Henderson et al., 1991). Taken
together, it will be a problem to introduce bcl-2, an
oncogene. into human BM. as it could cause tumours or
autoimmune disease.
In this study, we also show that enforced expression of
bcl-2 gene in BM cells results in increased resistance to
apoptosis induced by topoisomerase inhibitors. Our results
are essentially in agreement with Miyashita and Reed (1992.
1993), who have recently demonstrated that bcl-2 gene trans-
fer increases the relative resistance or murine lymphoid cells
and human leukaemia cells to cell death and DNA fragmen-
tation induced by chemotherapeutic drugs such as methotrex-
ate, vincristine (Miyashita & Reed, 1992) and VP-16
(Miyashita & Reed, 1993). The bcl-2 gene might therefore
interfere with a final common pathway for cell death that can
be activated by multiple mechanisms.
In conclusion, our findings suggest the possibility that
enforced expression of the bcl-2 gene in BM cells using gene
transfer techniques may enable rescue from myelosuppression
(BM cell death) induced by chemotherapeutic agents such as
topoisomerase inhibitors. We are at present attempting to
determine whether the bcl-2 gene can be used to rescue
chemotherapy-induced myelosuppression in an in vivo model.
without inhibiting the cytotoxic effect of agents on tumour
cells.
Abbreviadoas
rhG-CSF. recombinant human granulocy-te colony-stimulating fac-
tor; CPT. camptothecin; VP-16. etoposide; MAb. monoclonal
antibody.
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